Announcements Trials

Browse Landscape

Status

Completed 585 Active not recruiting 298 Recruiting 236 Terminated 220 Unknown 114 Withdrawn 76 Not yet recruiting 32 Suspended 10 Enrolling by invitation 5 No longer available 3 Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

Afatinib 3 3-Iodobenzylguanidine 3 niraparib 2 lenvatinib 2 ibrutinib 2 gallium 68 PSMA-11 2 abemaciclib 2 Trastuzumab 2 Sunitinib 2 Ramucirumab 2 Oxaliplatin 2 Magnetic Resonance Spectroscopy 2 Gefitinib 2 Fluorouracil 2 Capecitabine 2 Amifampridine 2 Abiraterone Acetate 2 zenocutuzumab 1 vorasidenib 1 tucatinib 1 trilaciclib 1 trifluridine tipiracil drug combination 1 tovorafenib 1 talquetamab 1 tafasitamab 1 selpercatinib 1 sacituzumab govitecan 1 ripretinib 1 pralsetinib 1 ponatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × Nivolumab × Clear all

NCT03126643 2021-11-29

Expanded Access to Nivolumab (Opdivo)

Bristol-Myers Squibb

Approved for marketing

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡